Christopher B. Ehrlich - 30 May 2025 Form 4 Insider Report for CERO THERAPEUTICS HOLDINGS, INC. (CERO)

Role
Chairman and CEO, Director
Signature
/s/ Andrew Kucharchuk, Attorney-in-Fact
Issuer symbol
CERO
Transactions as of
30 May 2025
Transactions value $
$0
Form type
4
Filing time
02 Jun 2025, 17:04:25 UTC
Previous filing
06 Mar 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ehrlich Christopher B Chairman and CEO, Director CERO THERAPEUTICS HOLDINGS, INC., 201 HASKINS WAY, SUITE 230, SOUTH SAN FRANCISCO /s/ Andrew Kucharchuk, Attorney-in-Fact 02 Jun 2025 0001293973

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERO Stock Option (Right to Buy) Award $0 +61,843 $0.000000 61,842 30 May 2025 Common Stock 61,842 $0.4454 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the 1/3 time-based portion of an award of options to purchase 185,529 shares, vesting in equal monthly installments on the 4th of each month from July 4, 2025 through December 4, 2025, with the remaining portion subject to performance conditions.

Remarks:

Exhibit 24 - Power of Attorney.